Clinotech Diagnostics & Pharmaceuticals Inc. proudly introduces a groundbreaking solution for malaria care: a transdermal, microneedle-based patch that delivers potent antimalarial medications without the drawbacks of traditional oral therapies. Drawing on extensive research and collaboration with international partners, our innovative approach harnesses the power of artemisinin-based combination therapies (ACTs)—specifically, artemether and lumefantrine—in a dissolving microneedle patch.
Malaria remains a devastating threat, particularly in sub-Saharan Africa, where children under five years old are most vulnerable. Traditional oral medications often face challenges like drug resistance, low bioavailability, and gastrointestinal side effects—all of which can undermine treatment success. Our minimally invasive patch, however, bypasses these barriers by delivering targeted medication directly through the skin, ensuring a prolonged release that maintains optimal drug levels in the bloodstream for up to five to seven days. This not only enhances patient comfort and adherence but significantly boosts efficacy and reduces overall drug requirements.
Clinotech’s solution goes beyond innovation in drug delivery. Through the local cultivation of Artemisia annua—the plant source of artemisinin—and in-country transformation into artemether, we aim to empower communities with accessible, cost-effective malaria treatments while fostering economic growth. We invite investors and global health partners to join us in redefining the malaria treatment landscape and saving countless lives with this revolutionary non-invasive therapy. Contact us today to learn more about partnership and investment opportunities.